Docstoc

Prospectus - AMERICAN BIO MEDICA CORP - 8-9-2002

Document Sample
Prospectus - AMERICAN BIO MEDICA CORP - 8-9-2002 Powered By Docstoc
					Filed Pursuant to Rule 424(b)(3) Registration No. 333-50230 Prospectus Supplement No. 11 Dated August 8, 2002 (to Prospectus November 30, 2000)

AMERICAN BIO MEDICA CORPORATION
This Prospectus Supplement is part of the Prospectus dated November 30, 2000 related to an offering of up to 2,361,733 shares of our common stock by the persons identified as the "selling shareholder" in the Prospectus. Recent Developments. Attached hereto is: - Our Quarterly Report on Form 10-QSB for the period ending June 30, 2002, filed with the Commission on August 8, 2002 The date of this Prospectus Supplement is August 9, 2002.

SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-QSB [x] Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2002. [ ] Transition report under Section 13 or 15(d) of the Securities Exchange
Act of 1934. For the transition period from to

Commission File Number: 0-28666

AMERICAN BIO MEDICA CORPORATION (Exact name of small business issuer as specified in its charter) New York 14-1702188 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 122 Smith Road, Kinderhook, New York 12106 (Address of principal executive offices) 800-227-1243 (Issuer's telephone number) Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] State the number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date: 20,609,548 Common Shares as of August 7, 2002 Transitional Small Business Disclosure Format: Yes [ ] No [X]

PART I FINANCIAL INFORMATION American Bio Medica Corporation Balance Sheets June 30, December 31,
2002 (Unaudited) -----------$ 537,000 2001 -----------$ 288,000

Assets Current assets: Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of $70,000 at June 30, 2002 and December 31, 2001 Other receivables Inventory Prepaid expenses and other current assets Total current assets Property, plant and equipment, net Restricted cash Other assets Total Assets Liabilities and Stockholders' Equity Current liabilities: Accounts payable Accrued expenses Customer advance deposits Wages payable Current portion of capital lease obligations Current portion of notes payable Total current liabilities Long term portion of capital lease obligations Long term portion of notes payable Long term portion of unearned grant Total liabilities Stockholders' equity: Preferred stock; par value $.01 per share; 5,000,000 shares authorized; none issued and outstanding Common stock; par value $.01 per share; 50,000,000 shares authorized; 20,609,548 shares issued and outstanding at June 30, 2002 and December 31, 2001 Additional paid-in capital Subscription receivable Due from officer/director/shareholder (collateralized by 1,000,000 shares of the Company's common stock) Treasury stock Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity

1,447,000 91,000 1,705,000 47,000 -----------3,827,000 1,423,000 7,000 -----------$ 5,257,000 ============

882,000 171,000 2,087,000 90,000 -----------3,518,000 1,455,000 106,000 7,000 -----------$ 5,086,000 ============

$

893,000 435,000 162,000 209,000 17,000 41,000 -----------1,757,000 2,000 687,000 50,000 -----------2,496,000 ------------

$

1,064,000 562,000 243,000 114,000 19,000 24,000 -----------2,026,000 10,000 696,000 -----------2,732,000 ------------

207,000 17,817,000 (416,000) (14,847,000) -----------2,761,000 -----------$ 5,257,000 ============

207,000 17,765,000 (5,000) (437,000) (23,000) (15,154,000) -----------2,353,000 -----------$ 5,086,000 ============

See accompanying notes to financial statements

American Bio Medica Corporation Statements of Operations

(Unaudited)
For The Six Months Ended June 30, ---------------------------2002 2001 ----------------------Net sales Cost of goods sold Gross profit Operating expenses: Research and development Selling and marketing General and administrative $ 4,872,000 $ 3,362,000

2,120,000 -----------2,752,000 -----------169,000 1,142,000 1,156,000 -----------2,467,000 -----------285,000 ------------

1,183,000 -----------2,179,000 -----------320,000 1,228,000 1,839,000 -----------3,387,000 -----------(1,208,000) -----------(169,000) 600,000 35,000 (12,000) -----------454,000 -----------$ (754,000) ============ $ (0.04) ============ $ (0.04) ============ 18,006,460 -----------18,006,460 ============

Operating income/(loss) Other income (expense): Loss on disposition of assets Other income Interest income Interest expense

45,000 (24,000) -----------21,000 -----------$ 306,000 ============ $ 0.02 ============ $ 0.01 ============ 20,609,548 861,068 -----------21,470,616 ============

Net income/(loss) attributable to common shareholders Basic and diluted income/(loss) per common share Fully diluted income/(loss) per common share Weighted average shares outstanding basic Dilutive effect of stock options and warrants Weighted average shares outstanding - fully diluted

See accompanying notes to financial statements

American Bio Medica Corporation Statements of Operations

(Unaudited)
For The Three Months Ended June 30, ---------------------------2002 2001 ----------------------Net sales Cost of goods sold Gross profit Operating expenses: Research and development Selling and marketing General and administrative $ 2,663,000 $ 1,463,000

1,179,000 -----------1,484,000 -----------37,000 608,000 593,000 -----------1,238,000 -----------246,000 ------------

417,000 -----------1,046,000 -----------145,000 731,000 909,000 -----------1,785,000 -----------(739,000) -----------(166,000) 600,000 21,000 (5,000) -----------450,000 -----------$ (289,000) ============ $ (0.02) ============ 17,995,548 -----------17,995,548 ============

Operating income/(loss) Other income (expense): Gain/(Loss) on disposition of assets Other income Interest income Interest expense

18,000 (12,000) -----------6,000 -----------$ 252,000 ============ $ 0.01 ============ 20,609,548 861,068 -----------21,470,616 ============

Net income/(loss) attributable to common shareholders Basic and diluted income/(loss) per common share Weighted average shares outstanding basic Dilutive effect of stock options and warrants Weighted average shares outstanding - fully diluted

See accompanying notes to financial statements

American Bio Medica Corporation Statements of Cash Flows

(Unaudited)
For The Six Months Ended June, -----------------------2002 2001 ----------------$ 306,000 75,000 16,000 (26,000) (565,000) 80,000 383,000 43,000 106,000 (171,000) (128,000) 94,000 (81,000) --------132,000 --------(43,000) --------(43,000) --------50,000 111,000 20,000 (8,000) (3,000) (10,000) --------160,000 --------249,000 288,000 --------$ 537,000 ========= $(754,000) 62,000 (166,000) (29,000) 102,000 564,000 74,000 (144,000) 7,000 (128,000) 211,000 310,000 --------109,000 --------(104,000) 18,000 --------(86,000) ---------

Cash flows from operating activities: Net income/(loss) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation Non cash compensation expense Accrued interest, related party Loss on sale of investments Changes in: Accounts receivable Other receivables Inventory Prepaid expenses and other current assets Restricted cash Accounts payable Accrued expenses Wages payable Customer advance deposits Net cash provided by operating activities Cash flows from investing activities: Purchase of property, plant and equipment Proceeds from sale of investments Net cash provided by/(used in) investing activities Cash flows from financing activities: Proceeds from convertible grant Proceeds from sale of treasury stock Proceeds from revolving line of credit Long term debt payments Revolving line of credit payments Settlement of registration rights agreement Capital lease payments Net cash provided by financing activities Net increase in cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Supplemental disclosures of cash flow information Cash paid during year for: Interest

26,000 (7,000) --------19,000 --------42,000 91,000 --------$ 133,000 =========

$ 13,000 =========

$ 8,000 =========

See accompanying notes to financial statements

Notes to financial statements (unaudited) June 30, 2002 Note A - Basis of Reporting The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items), which are considered necessary for a fair presentation of the financial position of American Bio Medica Corporation (the "Company" or "ABMC") at June 30, 2002, and the results of its operations, and cash flows for the six month and three-month periods then ended. The results of operations for the six-month and three month periods ended June 30, 2002 are not necessarily indicative of the operating results for the full year. These financial statements should be read in conjunction with the Company's audited financial statements and related disclosures for the eight months ended December 31, 2001 included in the Company's Form 10-KSB. During the eight months ended December 31, 2001, the Company sustained a net loss of $1,631,000 including other income of $259,000 resulting from a settlement for outstanding amounts owed to the Company's former legal counsel in its patent litigation and had net cash outflows from operating activities of $1,810,000. During the six months ended June 30, 2002, the Company had net income of $306,000, and had net cash provided by operating activities of $132,000. The Company continued to take steps to improve its financial prospects including penetrating the direct sales market, acquiring the technology and resources necessary to enter the forensic market for testing for abuse of Oxycodone, penetrating the market for the OralStat6 saliva based drug of abuse test and other measures to enhance profit margins. The Company believes that its current cash balances, and cash generated from operations will be sufficient to fund operations for the next twelve months. If cash generated from operations is insufficient to satisfy the Company's working capital and capital expenditure requirements, the Company may be required to sell additional equity or debt securities or obtain additional credit facilities. There is no assurance that such financing will be available or that the Company will be able to complete financing on satisfactory terms, if at all. NEW ACCOUNTING STANDARDS On June 29, 2001, Statement of Financial Accounting Standards (SFAS) No. 141, "Business Combinations," was approved by the Financial Accounting Standards Board (FASB). SFAS No. 141 requires the purchase method of accounting to be used for all business combinations initiated after June 30, 2001. The Company has adopted this Standard, however, the adoption of this Standard did not have a material effect on our financial condition, results of operations or cash flows. On June 29, 2001, SFAS No. 142, "Goodwill and Other Intangible Assets" was approved by the FASB. SFAS No. 142 changes the accounting for goodwill from an amortization method to an impairment-only approach. Amortization of goodwill, including goodwill recorded in past business combinations, will cease upon adoption of this statement. We adopted SFAS No. 142 effective January 1, 2002, however the adoption of this Standard did not have a material effect on our financial condition, results of operations or cash flows. In August 2001, the FASB issued SFAS No. 143, Accounting for Asset Retirement Obligations. SFAS No. 143 requires the fair value of a liability for an asset retirement obligation to be recognized in the period in which it is incurred if a reasonable estimate of fair value can be made. The associated asset retirement costs are capitalized as part of the carrying amount of the long-lived asset. SFAS No. 143 is effective for fiscal years beginning after June 15, 2002. We do not expect the adoption of this Standard to have a material effect on our financial condition, results of operations or cash flows. In August 2001, the FASB issued SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, which supersedes SFAS No. 121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of, and the accounting and reporting provisions of APB No. 30. SFAS No. 144 addresses financial accounting and reporting for the impairment or disposal of long-lived assets and is effective for fiscal years beginning after December 15, 2001, and interim periods within those fiscal years. The Company has adopted this Standard, however, the adoption of this Standard did not have a material effect on our financial condition, results of operations or cash flows.

In May 2002, the FASB issued Statement No. 145, "Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB 13, and Technical Corrections as of April, 2002." This statement rescinds previously issued pronouncements relating to reporting gains and losses from extinguishments of debt to satisfy sinking-fund requirements, and accounting for intangible assets of motor carriers, amends the pronouncement on accounting for leases, and also amends various other pronouncements to make various technical corrections, clarify meanings, or describe their applicability under changed conditions. The Company does not believe that this statement will have a material impact on its financial statements. Note B - Net Income or Loss Per Common Share Basic net income or loss per share is calculated by dividing the net income or loss by the weighted average number of outstanding common shares during the period. Diluted net income or loss per share includes the weighted average dilutive effect of stock options and warrants. Note C - Litigation In June 1999, Richard Davidson filed a lawsuit against the Company in New York. Davidson claims that two placement memoranda dated September 15, 1992 and February 5, 1993, obligates the Company to issue him 1,155,601 ABMC common shares. He claims he is entitled to the common shares in consideration of brokering the acquisitions subject to the Share Exchange Agreement with Dr. Robert Friedenberg (Friedenberg also filed suit against the Company and the case was dismissed in September 1999). In addition, Davidson is claiming a finder's fee of 5% of the funds raised by the September 1992 private placement. He alleges that a sum of $1 million was raised. He also claims he is entitled to a consulting fee of $24,000. Management denies the claims and is vigorously contesting the suit. A trial date was set for November 2000; however, the Company filed a motion for summary judgment against Davidson and Davidson cross-moved for summary judgment. In July 2001, the Company's motion for summary judgment was denied. In August 2001 the Company filed a Notice of Appeal related to the court's denial of the Company's motion for summary judgment. The court is currently considering Davidson's cross-motion for summary judgment, which the Company opposed in September 2001. The Company filed its brief to appeal the denial of the Company's summary judgment motion on March 15, 2002 and the Court is considering this appeal. A trial date had been set for May 6, 2002 but has since been postponed by the Court. A new trial date has not been set as of the date of this report, nor has the court made a decision on Davidson's cross motion for summary judgment. Management believes based on consultation with counsel, that it has substantial and compelling defenses to Davidson's claims and there is a reasonable chance that the Company would prevail if the matter were to go to trial. In June 1995 the Company filed a lawsuit against Jackson Morris, the lawyer engaged to draft and advise the Company on the Share Exchange Agreement with Dr. Robert Friedenberg. Morris, who had been recommended to the Company by Dr. Friedenberg and whose fees were paid by the Company, was alleged to have breached his fiduciary duty to the Company in several ways, including by later advising Friedenberg, individually, on how to rescind the Share Exchange Agreement as well as testifying for Friedenberg over the Company's objections and in violation of his obligations to the Company. Morris was also charged with negligence in drafting the Share Exchange Agreement. The Company's lawsuit demanded damages in the amount of $1,000,000. Morris counterclaimed as a party to the Share Exchange Agreement and sought common shares. The basis of all of Mr. Morris' claims stemmed from the Friedenberg claim. On July 27, 2001, the Company settled the lawsuit against Mr. Morris. The Company has issued 115,000 shares of the Company's common stock to Mr. Morris as settlement of all outstanding claims. The Company filed a registration statement related to these shares which was declared effective June 14, 2002. Note D - Reclassifications Certain items have been reclassified to conform to the current presentation.

Item 2. Management's Discussion and Analysis or Plan of Operation MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE SIX MONTHS AND THREE MONTHS ENDED JUNE 30, 2002 AND 2001 The following discussion of the Company's financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere in this document. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that in addition to the description of historical facts contained herein, this report contains certain forward-looking statements that involve risks and uncertainties as detailed herein and from time to time in the Company's other filings with the Securities and Exchange Commission and elsewhere. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those, described in the forward-looking statements. These factors include, among others: (a) the Company's fluctuations in sales and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) product development risks; (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; and (f) pending litigation. (see Note C - Litigation in the notes to the financials statements included in Part I of this report). Results of operations for the six months ended June 30, 2002 as compared to the six months ended June 30, 2001 Net sales were $4,872,000 for the six months ended June 30, 2002 as compared to $3,362,000 for the six months ended June 30, 2001, representing an increase of $1,510,000 or 44.9%. Direct sales have surpassed distributor sales as the most significant component of the Company's net sales, comprising approximately 48.4% of net sales. During the six months ended June 30, 2002, the Company continued its extensive program to market and distribute its primary product, the Rapid Drug Screen(R). The Company has undertaken an aggressive program aimed at rebuilding relationships with the Company's key distributors, building relationships with new distributors, and has reorganized and expanded the sales group to focus on ABMC's core business, the sale of the Rapid Drug Screen and other drugs of abuse test kits. Management believes sales from its urine based drug test kits and the OralStat6(TM) saliva based test will continue to grow as a result of this focus on the core business. Cost of goods sold for the six months ended June 30, 2002 was $2,120,000 or 43.5% of net sales as compared to $1,183,000 or 35.2% of net sales for the six months ended June 30, 2001. This increase in percentage is the result of larger volume sales at lower margins. Costs of raw materials, labor and overhead associated with manufacturing have remained relatively consistent during the six months ended June 30, 2002. While revenues increased 44.9% in the six months ended June 30, 2002, research and development costs decreased $116,000, or 36.3%, selling and marketing expenses decreased $59,000 or 4.8%, and general and administrative costs decreased $683,000 or 37.1%. Total operating expenses were $2,529,000 or 51.9% of revenues for the six months ended June 30, 2002 compared to $3,387,000 or 100.7% of revenues for the six months ended June 30, 2001. Research and development expenses for the six months ended June 30, 2002 were $169,000 compared to $320,000 for the six months ended June 30, 2001. This decrease was primarily due to decreased costs relating to the completion of the Company's joint project with Abbott Laboratories in the first quarter of fiscal 2001 offset by the amortization of the Company's licensing fee relating to the distribution of the OralStat6 test in the first quarter of 2002. Management expects increases in R&D as it explores new markets and uses for its immunoassay technology. Offsetting R&D expense in the six months ended June 30, 2002 is $35,000 received from a vendor for whom the Company performed R&D services.

Selling and marketing expense declined in the six months ended June 30, 2002 primarily due to savings of $40,000 in sales salaries and commissions and $26,000 in consulting expenses offset by increases of $14,000 in sales travel and other selling expenses. Sales salaries and commissions declined due to changes in the sales compensation structure focusing more attention on compensation for growth of the business as well as the inclusion of sign on bonuses paid to sales professionals in 2001 that did not recur in 2002. Consulting expense declined due to a reduction in the use of third party professional services. Marketing and promotion costs were $95,000 or 1.9% of net revenues in the first six months of 2002 compared to $102,000 or 3.0% of revenues for the same period in 2001. This reduction is the result of fewer individuals focused on marketing and less spending on promotional efforts during the first two quarters of 2002 while management re-evaluates it's strategy. Additional expense in marketing and promotion is expected in the third and fourth quarters of 2002. General and administrative expense decreased $683,000 in the first six months of 2002 to $1,156,000 or 23.7% of net revenues compared to $1,839,000 or 54.7% for the same period in 2001. This decrease is a result of a decreases in investor relations costs, legal fees, accounting fees, office salaries and bad debt expense, as described in the following six paragraphs. Investor relations costs decreased $164,000 in the six months ended June 30, 2002 compared to the same period in 2001. These costs included two full time positions in addition to travel expenses for two board members representing the Company in 2001. In 2002 one of the two full time investor relations positions is now accounted for as office salaries as a result of a change in responsibilities, and travel is limited to the one individual still included in Investor Relations. Legal fees for the six months ended June 30, 2002 were $172,000 or 3.5% of net sales, a decrease of $612,000, compared to legal fees of $784,000 or 23.3% of net sales for the six months ended June 30, 2001. This decrease in legal fees was primarily due to the settlement of patent litigation in the fourth quarter of the fiscal year ended April 30, 2001. Accounting fees for the six months ended June 30, 2002 were $41,000 or .8% of net sales, a decrease of $80,000, compared to accounting fees of $121,000 or 3.6% of net sales for the six months ended June 30, 2001. Accounting fees in 2001 include costs for the year end audit due to the change in the company's fiscal year. Office salaries for the six months ended June 30, 2002 were $278,000 or 5.7% of net sales, a decrease of $99,000, compared to office salaries of $377,000 or 11.2% of net sales for the six months ended June 30, 2001. However, the six months ended June 30, 2001 included severance expense of approximately $150,000 that did not recur in 2002. The six months ended June 30, 2002 includes additional resources in quality assurance as well as the reclassification of a position from investor relations to office salaries due to a change in that individual's responsibilities. Non cash compensation was $16,000 for the six months ended June 30, 2002. This charge relates to options granted to a former employee in exchange for consulting services and is being amortized over a vesting period of one year ending January 31, 2003. Bad debt expense decreased to $10,000 for the six months ended June 30, 2002, from $40,000 for the six months ended June 30, 2001. Included in 2001 was $27,000, related to one customer. Management implemented a focused effort on collection and management of receivables in late 2001. Management believes that the amount of selling and marketing costs and general and administrative costs may increase as the Company creates the necessary infrastructure to achieve the Company's worldwide drug test marketing and sales goals, continues its penetration of the direct sales market and leverages new product initiatives. However, management has implemented initiatives to control the rate of increase of these costs to be more consistent with the expected sales growth rate of the Company.

Results of operations for the three months ended June 30, 2002 as compared to the three months ended June 30, 2001 Net sales were $2,663,000 for the three months ended June 30, 2002 as compared to $1,463,000 for the three months ended June 30, 2001, representing an increase of $1,200,000 or 82.0%. During the three months ended June 30, 2002, the Company continued its extensive program to market and distribute its primary product, the Rapid Drug Screen(R). Cost of goods sold for the three months ended June 30, 2002 was $1,179,000 or 44.3% of net sales as compared to $417,000 or 28.5% of net sales for the three months ended June 30, 2001. This increase in percentage is the result of larger volume sales at lower margins. Included in the three months ended June 30, 2002 is a write off of approximately $21,000 of expired Drug Detector inventory. Costs of raw materials, labor and overhead associated with manufacturing have remained relatively consistent during the three months ended June 30, 2002. While revenues increased in the three months ended June 30, 2002, research and development costs decreased $73,000, selling and marketing expenses decreased $123,000, and general and administrative costs decreased $316,000. Total operating expense was $1,273,000 or 47.8% of revenues for the three months ended June 30, 2002 compared to $1,785,000 or 122.0% of revenues for the three months ended June 30, 2001. Research and development expenses for the three months ended June 30, 2002 were $37,000 compared to $145,000 for the three months ended June 30, 2001. The decrease is primarily due to the reallocation of R&D resources to inventory production to meet increased sales in the three months ended June 30, 2002. Management expects increases in R&D as it explores new markets and uses for its immunoassay technology. Offsetting R&D expense in the three months ended June 30, 2002 is $35,000 received from a vendor for whom the Company performed R&D services. Sales and marketing expense declined in the three months ended June 30, 2002 primarily due to savings of $133,000 in sales salaries and commissions offset by increases of $30,000 in sales travel and other selling expenses. Sales salaries and commissions declined due to changes in the sales compensation structure focusing more attention on compensation for growth of the business as well as the inclusion of sign on bonuses paid to sales professionals in 2001 that did not recur in 2002. General and administrative expense decreased $316,000 in the first three months of 2002 to $593,000 or 22.3% of net revenues compared to $909,000 or 62.1% for the same period in 2001. This decrease is a result of decreases in investor relations costs, legal fees, accounting fees and bad debt expense, offset by an increase in office salaries, as described in the following five paragraphs. Investor relations costs decreased $62,000 in the three months ended June 30, 2002 compared to the same period in 2001. These costs included two full time positions in addition to travel expenses for two board members, representing the Company, in 2001. In 2002 one of the two full time investor relations positions is now accounted for as office salaries as a result of a change in responsibilities, and travel is limited to the one individual still included in Investor Relations. Legal fees for the three months ended June 30, 2002 were $64,000 or 2.4% of net sales, a decrease of $302,000, when comparing legal fees of $366,000 or 25.0% of net sales for the three months ended June 30, 2001. This decrease in legal fees was primarily due to the settlement of patent litigation in the fourth quarter of the 2001 fiscal year. Accounting fees for the three months ended June 30, 2002 were $28,000 or 1.1% of net sales, a decrease of $24,000, compared to accounting fees of $52,000 or 3.6% of net sales for the three months ended June 30, 2001. Accounting fees in 2001 include costs for the year-end audit due to a change in the company's fiscal year. Office salaries for the three months ended June 30, 2002 were $132,000 or 5.0% of net sales, an increase of $31,000, compared to office salaries of $101,000 or 6.9% of net sales for the three months ended June 30, 2001. This increase is due to the additional resources in quality assurance as well as the reclassification of a position from investor relations to office salaries due to a change in that individual's responsibilities.

Bad debt expense decreased to $10,000 for the three months ended June 30, 2002, from $30,000 for the three months ended June 30, 2001. Offsetting the bad debt expense in 2002 are recoveries of $4,000. Management implemented a focused effort on collection and management of receivables in late 2001. Management believes that the amount of selling and marketing costs and general and administrative costs may increase as the Company creates the necessary infrastructure to achieve the Company's worldwide drug test marketing and sales goals, continues its penetration of the direct sales market and leverages new product initiatives. However, management has implemented initiatives to control the rate of increase of these costs to be more consistent with the expected sales growth rate of the Company. LIQUIDITY AND CAPITAL RESOURCES AS OF JUNE 30, 2002 The Company's cash requirements depend on numerous factors, including product development activities, ability to penetrate the direct sales market, market acceptance of its new products, and effective management of inventory levels in response to sales forecasts. The Company expects to devote substantial capital resources to continue its product development, expand manufacturing capacity and continue research and development activities. The Company will examine other growth opportunities including strategic alliances and expects such activities will be funded from existing cash and cash equivalents, issuance of additional equity or debt securities or additional borrowings subject to market and other conditions. The Company believes that its current cash balances, and cash generated from operations will be sufficient to fund operations for the next twelve months. If cash generated from operations is insufficient to satisfy the Company's working capital and capital expenditure requirements, the Company may be required to sell additional equity or debt securities or obtain additional credit facilities. There is no assurance that such financing will be available or that the Company will be able to complete financing on satisfactory terms, if at all. The Company has working capital of $2,070,000 at June 30, 2002 as compared to working capital of $1,492,000 at December 31, 2001. The Company has historically satisfied its net working capital requirements through cash generated by proceeds from private placements of equity securities with institutional investors. The Company has never paid any dividends on its Common Shares. The Company anticipates that all future earnings, if any, will be retained for use in the Company's business and it does not anticipate paying any cash dividends. Net cash provided by operating activities was $132,000 for the six months ended June 30, 2002 compared to $109,000 for the six months ended June 30, 2001. The net cash provided by operating activities for the six months ended June 30, 2002 was primarily due to net income of $306,000, offset by a net change of $265,000 in operating assets and liabilities. The net cash provided by operating activities in the six months ended June 30, 2001 was primarily due to net changes in operating assets and liabilities of $996,000, offset by the net loss of $754,000. Net cash used in/provided by investing activities was $43,000 for the six months ended June 30, 2002 for the purchase of property, plant and equipment, compared to net cash used in investing activities of $86,000 for the six months ended June 30, 2001. The net cash used in investing activities in 2001 was primarily due to proceeds from the sale of investments of $18,000, offset by the purchase of property, plant and equipment of $104,000. Net cash provided by financing activities was $160,000 for the six months ended June 30, 2002, consisting of proceeds from a convertible grant from the Columbia Economic Development Corp. of $50,000 relating to assistance in the acquisition of the Kinderhook facility, proceeds from a revolving line of credit of $20,000, proceeds from the sale of treasury stock of $111,000, offset by capital lease and long term debt payments of $9,000 each, and payments on the revolving line of credit of $3,000. The net cash provided by financing activities for the six months ended June 30, 2001 was $26,000 for the settlement of a registration rights agreement offset by capital lease payments of $7,000.

At June 30, 2002 and 2001, the Company had cash and cash equivalents of $537,000 and $133,000, respectively. In addition the Company has a $40,000 revolving line of credit bearing an interest rate of prime plus 1.75% secured by its accounts receivable. At June 30, 2002, the Company had an outstanding balance on this line of credit of approximately $17,500. The Company's primary short-term capital and working capital needs are to increase and improve its manufacturing and production capabilities, establish adequate inventory levels to support expected sales, continue to support its research and development programs, open new distribution opportunities and focus sales efforts on high potential sectors of the drugs of abuse testing market.

PART II OTHER INFORMATION Item 1. Legal Proceedings: See Note C - Litigation in the Notes to Financial Statements included in this report for a description of pending legal proceedings in which the Company is a party. Item 2. Changes in Securities None. Item 3. Defaults upon Senior Securities None. Item 4. Submission of Matters to a Vote of Security-Holders The following matters were voted upon at the Company's Annual Meeting of Shareholders (the "Meeting") held at the Company's laboratory facility in Bridgeport, New Jersey on June 20, 2002. PROPOSAL 1 - ELECTION OF DIRECTORS Total shares voted: 17,499,943 Outstanding shares: 20,609,548 Percent of shares voted: 84.9
Director --------Stan Cipkowski Edmund Jaskiewicz Gerald Moore Robert L. Aromando, Jr. Denis O'Donnell, M.D. D. Joseph Gersuk For --16,962,101 17,052,391 17,299,441 16,290,951 17,100,166 17,096,516 Pct. ---96.9 97.4 98.9 93.0 97.7 97.7 Withheld --------537,842 447,552 200,502 1,208,992 399,777 403,427 Pct. ---3.1 2.6 1.1 6.9 2.3 2.3

All seven nominees up for election to the Board of Directors were elected and all seven Directors term of office continued after the Meeting. Item 5. Other Information None. Item 6. Exhibits and Reports on Form 8-K (a) Exhibits 10.17 Promissory Note by and between the Company and Columbia Economic Development Corporation ("CEDC"). 99.1 Certification of the Chairman of the Board and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 99.2 Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (b) Reports on Form 8-K None

SIGNATURES In accordance with the requirements of the Exchange Act, the registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AMERICAN BIO MEDICA CORPORATION (Registrant)
By: /s/Keith E. Palmer -------------------------------------EVP of Finance, Chief Financial Officer and Treasurer (Principal Accounting Officer and duly authorized Officer)

Dated: August 7, 2002

Exhibit 10.17 PROMISSORY NOTE $100,000.00 Date: June 6,2002 AMERICAN BIO MEDICA CORPORATION Borrower 122 Smith Road Kinderhook, New York 12106 Borrower's Address 1. BORROWER'S PROMISE TO PAY AMERICAN BIO MEDICA CORPORATION, a New York corporation, (the "Borrower" or the "Undersigned"), for value received, promises to pay to the order of COLUMBIA ECONOMIC DEVELOPMENT CORPORATION (hereinafter referred to as "CEDC," "Lender" or "Note Holder") the sum of ONE HUNDRED THOUSAND AND 00/100 ($100,000.00) DOLLARS (the "Principal") at 444 Warren Street, Hudson, New York 12534, which shall be paid at such rate and in accordance with such terms as indicated below. 2. RATE The Borrower shall pay interest at the rate indicated below (the "Interest Rate"). If the Borrower does not reach the employment goal of 55 full-time equivalent employees at the Borrower's Kinderhook, New York facility by March 31, 2004, the interest rate shall be three (3.0%) percent per annum, effective April 1, 2004. If the employment level at the Borrower's Kinderhook, New York facility shall fall below 45 full-time equivalent employees at any time after the date of this Note, then the interest rate shall not be three (3.0% ) percent per annum, and the preceding paragraph shall not apply. Instead, the interest rate shall be a variable interest rate equal to the Wall Street Journal prime rate as of the first business date in the preceding January, and the rate will be adjusted each January thereafter for the remaining term of the loan based on the Wall Street Journal prime rate on the first business date in January for each year thereafter. The Wall Street Journal prime rate is defined as the highest prime rate published in the Wall Street Journal. The interest rate referenced herein will become effective as of the date that the employment level at the Borrower's Kinderhook, New York facility falls below 45 full-time equivalent employees. The Lender is not required to deliver any notice to the Borrower of a change in the interest rate. However, upon request, the Lender shall provide the Borrower with information regarding the dates and amounts of the change in the interest rate. There is no maximum limit on the amount that the interest rate may change.

3. REPAYMENT TERMS The Borrower will repay this Note by making successive monthly payments of Principal and interest based upon the amount due amortized over a ten (10) year period commencing on the first day of the second month after repayment of the amount due on the Note is required, and ending on the first day of the one hundred twentieth (120) month thereafter when the remaining unpaid Principal and interest shall be due and payable in full. The Borrower will also make an interest only payment based on the amount due and the interest rate as set forth herein on the first day of the first month after repayment of the loan is due. 4. BUSINESS LOAN The Borrower represents and warrants that this Note evidences a loan for business or commercial purposes and is not a consumer transaction. 5. APPLICATION OF PAYMENTS Each payment received on this Note shall be applied first to interest due and then to the outstanding principal balance. However, if there are any additional amounts due to CEDC hereunder, such as late charges, CEDC may elect to apply any monies received for payment of such additional amounts due, prior to applying same toward payment of the principal balance. 6. COLLECTION OR ENFORCEMENT COSTS If it is necessary for CEDC to bring any action or proceeding in order to collect any amounts due hereunder or as a result of a breach of any of the terms or conditions herein, including an action or proceeding pursuant to Article 9 of the Uniform Commercial Code, or if CEDC is made a party to a lawsuit by virtue of this agreement, the Borrower shall be responsible for paying all costs, expenses and reasonable attorneys' fees incurred by CEDC in such lawsuit, action or proceeding, and also for all costs, expenses and reasonable attorneys' fees incurred by CEDC incidental to the care, preservation, processing and sale of the Collateral, or in any way relating to the rights of CEDC hereunder. 7. BINDING AGREEMENT;GOVERNING LAW The Note shall be binding upon the heirs, successors and assigns of the Borrower and CEDC. It shall be interpreted and construed in accordance with the laws of New York State. 8. MORE THAN ONE SIGNER If more than one person or entity signs this Note as a Borrower, the obligations contained herein shall be deemed joint and several and all references to "Borrower" shall apply to all persons signing this agreement both individually and jointly. -2-

9. DEFAULT The total unpaid balance of this Note shall become due and payable without notice or demand upon the occurrence of anyone of the following "Events of Default"; (a) default in any payment of principal or interest when due under this Note and the continuance thereof for twenty (20) days after the due date, except that the twenty-day period shall not apply for any payment due at the end of the term or upon demand, which shall be due immediately upon such date; (b ) default in any payment of late charges when due under this Note and the continuance thereof for ten (10) days after the due date; (c) failure to fulfill or perform any other term of this Note or to keep any promises made in this Note or related Term Loan Agreement, mortgage, building loan agreement or security agreement, if any; ( d) a false or incomplete statement in any information submitted to CEDC in connection with this Note; (e) entry of a judgment against the Borrower; (f) a significant decline in the value of any real or personal property securing payment of this Note; (g) business failure or dissolution of any Borrower; (h) death of the insured under any life insurance policy securing payment of this Note or the cancellation of the policy for any reason; (i) commencement of any bankruptcy, receivership or similar proceeding involving any Borrower as debtor; 0) transfer of any interest in the Collateral pledged or granted to the CEDC as a security interest, or any other breach by the Borrower with regard to the terms and conditions of the security instrument given by the Borrower to the Lender; (k) default by any guarantor of the Borrower with respect to any obligation of such guarantor to the Lender; (I) default with respect to any of the terms and conditions set forth in the commitment letter from the Lender to the Borrower dated January 29,2002; (m) Borrower fails to comply with reporting requirements of the United States of America Housing and Urban Development Agency relative to job creation and retention. 10. WAIVER The Borrower and all endorsers, sureties and guarantors hereof hereby jointly and severally waive presentment for payment, demand, notice of non-payment, notice of protest and/or notice of dishonor, and protest of this Note. 11. EXCESS INTEREST At no time shall the Interest Rate exceed the highest rate allowed by law for this type of loan. Should this occur or should the Lender ever erroneously collect interest at a rate which exceeds the applicable legal limit, such excess will be credited to principal. However, this shall not be grounds for voiding the Borrower's obligations hereunder and in such event, the Borrower's obligations shall be deemed to be automatically modified to conform with any such applicable legal limit. 12. GIVING OF NOTICES OR DEMANDS Any notice or other formal communication given either by Borrower or by the Lender will -3-

be in writing, and shall be deemed sufficiently given if delivered by anyone of the following methods: (i) personal delivery which, in case of notice to the Lender, shall be to an officer or principal thereof; (ii) certified or registered mail, return receipt requested, postage prepaid and properly addressed as set forth below; or (iii) Federal Express or other nationally recognized courier services providing written evidence of delivery .Addresses for receipt of notices are as follows:
To the Borrower: ---------------American Bio Medica Corporation 122 Smith Road Kinderhook, New York 12106 To the Lender: -------------Columbia Economic Development Corporation 444 Warren Street Hudson, New York 12534

Either party may change address for receipt of notices by written notice given to the other party in the manner provided above. 13. RIGHT TO TRANSFER CEDC may transfer or assign this Note and deliver all or any of its rights in the Collateral held as security there for to another party or entity which shall thereupon become vested of all of the powers and rights given to CEDC herein, and CEDC shall thereafter be forever relieved and fully discharged of any liability or responsibility to the Borrower. 14. LATE CHARGES In addition to any other payment required herein, the Borrower shall also be obligated to pay a late charge of five (5.0%) percent or Twenty-Five ($25.00) Dollars, which ever amount is greater for any payment due hereunder which is received by CEDC more than ten (10) days after such payment is due. This payment shall automatically be payable by the Borrower to CEDC, without demand, and the failure to pay same shall constitute a default in accordance with paragraph "9" of this Note. 15. ALL MODIFICATIONS IN WRITING No modification or waiver of any of the provisions of this Note shall be effective unless in writing, signed by an officer of CEDC and only to the extent therein set forth, nor shall any such waiver be applicable, except in the specific instance for which given. 16. WAIVER OF JURY TRIAL AND SETOFFS The Borrower hereby waives trial by jury and the right to interpose any setoffs of any kind in any litigation commenced by CEDC relating to this Note or any Collateral security for this Note. -4-

17. STRICT PERFORMANCE The failure of CEDC to immediately act with respect to any of its rights herein shall not be deemed to be a waiver on its part with respect to any such rights, and CEDC shall have the right to so act with respect to any of its rights herein at any time thereafter. 18. CROSS-DEFAULT The Borrower hereby covenants and agrees that any event constituting a default in the terms, covenants and conditions of any Notes, Mortgages, agreements or other obligations given to the Lender, or a default in the terms, covenants and conditions of any Notes, Mortgages, agreements or other obligations given to another Lender and secured by Collateral pledged to the Lender herein (including both real and personal property) shall be considered a default of the terms, covenants and conditions of this Note, and the Lender may take whatever action it deems necessary pursuant to said default. Furthermore, a default in the terms, covenants and/or conditions of this Note shall constitute a default in the terms, covenants and conditions of any other Notes, Mortgages, agreements or other obligations given by the Borrower to the Lender. 19. SECURED NOTE In addition to the protections given to the Lender under this Note, the Borrower has also given the Lender a mortgage and a security agreement on certain real and personal property (the "Security Instruments") dated the same date as this Note, which provides the Lender with certain rights as set forth herein and also sets forth certain obligations on the part of the Borrower. A default in any of the provisions of any Security Instrument shall constitute a default with respect to this Note. By granting a security interest in this Collateral, Borrower intends to provide the Lender with security for payment of said Note and obligation, including any extensions, modifications or renewals thereof. 20. SALE OR TRANSFER OF PROPERTY OR INTEREST THEREIN IS PROHIBITED The Borrower may not sell or otherwise transfer all or any part of any property pledged as collateral pursuant to any Security Instrument executed by the Borrower in connection with this transaction. In addition, if the Borrower is not a natural person, no beneficial interest in the Borrower, corporation, partnership or other entity may be sold or otherwise transferred to any other party without the express written consent of the Lender. If all or any part of the property or any interest in the property referred to herein is sold or otherwise transferred or if the beneficial interest in the Borrower, corporation, partnership or other entity is sold or otherwise transferred where the Borrower is not a natural person, the entire indebtedness under the Note and underlying Security Instruments shall become immediately due and payable. If the Borrower fails to pay these sums, the Lender may bring a lawsuit for foreclosure and sale or invoke any remedies permitted pursuant to this Note or any of the Security Instruments, without further notice or demand on the Borrower. -5-

21. BORROWER'S RIGHT TO PREPAY The Borrower shall have the right to make a full prepayment or partial prepayment of the principal due hereunder at any time, without penalty. When the Borrower makes a prepayment, the Borrower will tell the Lender, in writing, that it is doing so. If the Borrower makes a partial prepayment, there will be no change in the due dates or in the amount of the monthly payments unless otherwise agreed to in writing by the Lender . 22. REPAYMENT REQUIREMENT PURSUANT TO THIS NOTE The One Hundred Thousand and 00/lOO ($100,000.00) Dollars evidenced by this Note is in "the form of a conditional grant to the Borrower which grant does not need to be repaid as long as the Borrower attains and maintains certain employment thresholds referenced in the commitment letter, dated January 29,2002. If the Borrower does not maintain such employment thresholds, the grant will automatically convert into a loan which shall be repaid pursuant to the provisions of the commitment letter and this Note. Fifty Thousand and 00/lOO ($50,000.00) Dollars of the grant will be awarded at this time, with the provision that the Borrower must reach the employment goal of 55 full-time equivalent employees at its Kinderhook, New York facility by March 31, 2004. If the Borrower does not reach this employment goal by March 31, 2004, then the grant will automatically convert into a loan to be amortized over a ten (10) year period at three (3.0%) percent per annum interest in accordance with the provisions of this Note, and no further advances will be made to the Borrower. Provided that Borrower meets this employment goal of 55 full-time equivalent employees at its Kinderhook, New York facility by March 31, 2004, then the Borrower will be eligible for two (2) further advances of $25,000.00 each which will be made to the Borrower when Borrower achieves employment thresholds of 60 and 75 full-time equivalent employees at its Kinderhook, New York facility respectively. The opportunity to obtain further advances by the Borrower pursuant to the grant will expire on March 31,2006. Also, if the employment level at the Borrower's Kinderhook, New York facility shall fall below 45 full-time equivalent employees at any time after the date hereof and prior to March 31, 2012, and if the grant has reached the second or third advance when such employment falls below 45 full-time equivalent employees, then the grant will also convert into a loan and will be repaid to the Lender based upon the following schedule: o 90% of the total grant made, if employment falls below threshold in 2004, to be repaid over nine (9) years at the appropriate interest rate set forth in paragraph 2. o 80% of the total grant made, if employment falls below threshold in 2005, to be repaid over eight (8) years at the appropriate interest rate set forth in paragraph 2. o 70% of the total grant made, if employment falls below threshold in 2006, to be repaid over seven (7) years at the appropriate interest rate set forth in paragraph 2. -6-

o 60% of the total grant made, if employment falls below threshold in 2007, to be repaid over six (6) years at the appropriate interest rate set forth in paragraph 2. o 50% of the total grant made, if employment falls below threshold in 2008, to be repaid over five (5) years at the appropriate interest rate set forth in paragraph 2. o 40% of the total grant made, if employment falls below threshold in 2009, to be repaid over four (4) years at the appropriate interest rate set forth in paragraph 2. o 30% of the total grant made, if employment falls below threshold in 2010, to be repaid over three (3) years at the appropriate interest rate set forth in paragraph 2. o 20% of the total grant made, if employment falls below threshold in 2011, to be repaid over two (2) years at the appropriate interest rate set forth in paragraph 2. o 10% of the total grant made, if employment falls below threshold in 2012, to be repaid over one (1) year at the appropriate interest rate set forth in paragraph 2. IN WITNESS WHEREOF, this Note has been signed by the Borrower at Hudson, New York on June 6, 2002 AMERICAN BIO MEDICA CORPORATION, Borrower
By: /s/ Stan Cipkowski -------------------------------------------Stan Cipkowski, Exec. V.P. By: /s/ Keith E. Palmer ---------------------------------------Keith E. Palmer, Chief Financial Officer

STATE OF NEW YORK ) ) ss.: COUNTY OF COLUMBIA ) On the 6th day of June in the year 2002 before me, the undersigned, personally appeared Stan Cipkowski, personally known to me or proved to me on the basis of satisfactory evidence to be the individual(s) whose name(s) is (are) subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their capacity(ies), and that by his/her/their signature(s) on the instrument, the individual(s), or the person upon behalf of which the individual(s) acted, executed the instrument.
/s/ -----------------------------------Signature and Office of Individual taking acknowledgment

-7-

STATE OF NEW YORK COUNTY OF COLUMBIA

) ) )

ss.:

On the 6th day of June in the year 2002 before me, the undersigned, personally appeared Keith E. Palmer, personally known to me or proved to me on the basis of satisfactory evidence to be the individual(s) whose name(s) is (are) subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their capacity(ies), and that by his/her/their signature(s) on the instrument, the individual(s), or the person upon behalf of which the individual(s) acted, executed the instrument.
/s/ ---------------------------------Signature and Office of Individual taking acknowledgment

-8-

EXHIBIT 99.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of American Bio Medica Corporation (the "Company") on Form 10-QSB for the period ending June 30, 2002 as filed with the Securities and Exchange Commission on August 7, 2002 (the "Report"), I, Gerald A. Moore, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Gerald A. Moore ------------------Gerald A. Moore Chairman of the Board and Chief Executive Officer August 7, 2002

EXHIBIT 99.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of American Bio Medica Corporation (the "Company") on Form 10-QSB for the period ending June 30, 2002 as filed with the Securities and Exchange Commission on August 7, 2002 (the "Report"), I, Keith E. Palmer, Chief Financial Officer and Vice President of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Keith E. Palmer ------------------Keith E. Palmer Chief Financial Officer and Vice President August 7, 2002